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Abstract
Background: Recent Swedish and joint European guidelines on hyperlipidaemia stress the high coronary risk for
patients with already established arterio-sclerotic disease (secondary prevention) or diabetes. For the remaining
group, calculation of the ten-year risk for coronary events using the Framingham equation is suggested. There is
evidence that use of and adherence to guidelines is incomplete and that tools for risk estimations are seldom used.
Intuitive risk estimates are difficult and systematically biased. The purpose of the study was to examine how GPs
use knowledge of guidelines in their decisions to recommend or not recommend a cholesterol-lowering drug and
the reasons for their decisions.
Methods: Twenty GPs were exposed to six case vignettes presented on a computer. In the course of six screens,
successively more information was added to the case. The doctors were instructed to think aloud while
processing the cases (Think-Aloud Protocols) and finally to decide for or against drug treatment. After the six
cases they were asked to describe how they usually reason when they meet patients with high cholesterol values
(Free-Report Protocols). The two sets of protocols were coded for cause-effect relations that were supposed to
reflect the doctors' knowledge of guidelines. The Think-Aloud Protocols were also searched for reasons for the
decisions to prescribe or not to prescribe.
Results: According to the protocols, the GPs were well aware of the importance of previous coronary heart
disease and diabetes in their decisions. On the other hand, only a few doctors mentioned other arterio-sclerotic
diseases like stroke and peripheral artery disease as variables affecting their decisions. There were several
instances when the doctors' decisions apparently deviated from their knowledge of the guidelines. The arguments
for the decisions in these cases often concerned aspects of the patient's life-style like smoking or overweight-
either as risk-increasing factors or as alternative strategies for intervention.
Conclusions: Coding verbal protocols for knowledge and for decision arguments seems to be a valuable tool
for increasing our understanding of how guidelines are used in the on treatment of hypercholesterolaemia. By
analysing arguments for treatment decisions it was often possible to understand why departures from the
guidelines were made. While the need for decision support is obvious, the current guidelines may be too simple
in some respects.
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Background
The decision to recommend or not to recommend drug
treatment for individuals with high cholesterol values
should depend on an evaluation of the individual's risk
for future cardiovascular disease, primarily coronary heart
disease (CHD). The European guidelines [1] emphasise
the high risk for people with already established CHD or
other arterio-sclerotic manifestations such as stroke, tran-
sient ischaemic attacks (TIA) or peripheral artery disease
(PAD). For these so-called secondary prevention cases
pharmacological treatment should generally be justified
under the condition that life-style intervention has been
tried for a sufficiently long time. The cut-off values for ini-
tiating treatment, which are the same as the goal values for
treatment, are specified as 5.0 mmol/L for total choles-
terol, and 3.0 mmol/L for low-density-proteins (LDL).
The 1999 Swedish adaptation of the European guidelines
[2] stresses the high coronary risk for individuals with type
2 diabetes and suggests that they should be screened and
recommended treatment based on the same criteria as in
the secondary prevention situation. For the remaining
group of individuals with elevated cholesterol and/or ele-
vated LDL levels who are not at high risk for other reasons
(e.g. diagnosed as familial hypercholesterolaemia), the
decision to recommend a drug or not should be based on
a numerical estimate of the individual's absolute risk for a
future coronary event. The European and Swedish guide-
lines recommend that the absolute risk for a coronary
event within the next ten years should be calculated using
the so-called Framingham equation [3]. If the 10 -year risk
exceeds 20%, or if it exceeds 20% when the time span is
projected to the age of 60, drug treatment should be con-
sidered if life-style interventions have not sufficed.
Due to the vast number of different guidelines of rele-
vance for primary health care physicians, and the rapid
changes in guidelines in the field of cholesterol treatment,
we can assume that guidelines are not known in detail or
easily retrievable by all doctors. Even if the guidelines
were well known and/or easily retrievable, adherence to
them could vary due to different opinions and values on
the part of doctors. We can also assume that tools for risk
estimates are not always available or used when indicated
[4,5]. The consequences can be over- and undertreatment
as compared with the guidelines, which has been shown
by a review of medical records [6], and an inefficient use
of quite costly cholesterol-lowering drugs. An increased
understanding of how and why doctors' decisions on drug
treatment deviate from guidelines may be useful in for-
mulating and communicating guidelines and in teaching
in general within preventive cardiology.
In the present work, we used the think-aloud technique
[7] to find out how primary health care physicians make
decisions about simulated patient cases with hypercholes-
terolaemia in combination with other risk factors. In two
previous papers that were based on the same think-aloud
experiment, we investigated the validity of Think-Aloud
Reports compared with rating data for reflecting the deci-
sion process over time [8], and we analysed the impor-
tance of different patient characteristics and risk factors
regarding prescription decisions [9].
The aim of the present study was to investigate how gen-
eral practitioners use their knowledge about the guide-
lines on hyperlipidaemia in their decisions on drug
treatment, and what their arguments are for their deci-
sions concerning cases with different recommended treat-
ment according to the guidelines. We therefore analysed
how the verbal protocols reflected the doctors' knowledge
of guidelines with regard to the special status of individu-
als with CHD, other arterio-sclerotic manifestations, or
diabetes. We used the coding method described by Axel-
rod [10] in his construction of "cognitive maps". Briefly, a
cognitive map is a model of a person's belief system about
a limited domain and consists of a number of cause-effect
relations. The analysis of the verbal protocols according to
their cause-effect structure proved to be more suitable
than more complex coding schemes because of the quite
simple conceptual structure of our data.
As a separate analysis, we examined the evidence from the
verbal protocols regarding arguments for decisions to pre-
scribe or not to prescribe for different patient cases. In par-
ticular, the analysis of arguments can be interesting when
the participant seems to be aware of a certain aspect of the
guidelines, for example that the presence of CHD is a
strong indication for drug treatment for an elevated cho-
lesterol value, but still decides not to treat a patient with
these characteristics. Two kinds of verbal protocols were
used. The protocols from processing and deciding upon
the simulated cases (Think-Aloud Protocols) were com-
plemented by protocols from a task in which the doctors
were asked to describe how they usually reason in their
practice when drug prescription for elevated cholesterol
values may be indicated (Free-Report Protocols). In this
way the doctors not only got "a second chance" to express
their knowledge and decision rules concerning the risk
factors presented with the cases, but also to state their
rules and knowledge regarding diseases that were not rep-
resented in any of our case vignettes (e.g., stroke). Moreo-
ver, we could examine what factors other than the
traditional risk factors, such as those presented in the case
vignettes, seemed to influence decisions on drug treat-
ment. For example, we could expect some participants to
talk about the patient's compliance, side effects of drugs,
drug costs and so on as factors influencing the decision to
prescribe or not to prescribe for individuals with high cho-
lesterol values. These latter protocols were therefore exam-
ined not only concerning evidence of knowledge ofBMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/3
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guidelines but also concerning all variables affecting the
decision to prescribe or not to prescribe a drug for
hypercholesterolaemia.
Methods
Participants
Ten male and 10 female GPs aged 34 to 60 years (mean =
48.3) participated. They were all specialists in family med-
icine and had practised between one and 22 years (mean
= 11.4) as such. A total of 36 doctors from the southern
Stockholm area were contacted by telephone and twenty-
four agreed to participate. The remaining 12 doctors (five
males and seven females with mean age 47.0 years)
almost invariably reported a lack of time as their reason
for not participating. The four who later declined to par-
ticipate (usually by fax) were not asked for their reasons.
Design
The order of the cases was the same for all participants.
Cases with "Yes" and "No" decisions as the recommended
treatment according to the guidelines were mixed as
evenly as possible. In order to examine the validity of
think-aloud protocols, 10 of the participants were ran-
domly assigned to a condition where, in addition to
thinking aloud, they also rated their willingness to pre-
scribe a drug at regular intervals during each case. It was
shown in an earlier study that rating data and think-aloud
data corresponded closely concerning how they reflected
the directionality of the decision process, and were hence
considered to mutually validate each other [8]. In the
present paper the protocols from the two experimental
groups were not separated.
Cases
Six authentic clinical cases with a cholesterol level of at
least 5.5 mmol/L were selected to represent secondary pre-
vention, diabetes and primary prevention cases with a
spread of the 10 -year coronary risks. The central informa-
tion describing the six different cases, as well as the recom-
mended treatment according to Swedish guidelines are
described under Results (Table 4). The treatment recom-
mendations are based on the assumption that patients
with CHD, other arterio-sclerotic manifestations or diabe-
tes should be recommended drug treatment, while
patients who are free from these diseases should be rec-
ommended treatment if their estimated 10-year risk for a
coronary event exceeds 20%. All patients were assumed to
have tried for a reasonable amount of time to normalise
their cholesterol values with diet and exercise.
The different kinds of clinical information were presented
on six successive screens, and the information was divided
time-wise in the same way for all six cases. The order in
which this information was presented was arranged so as
to be as realistic as possible in relation to clinical practice
(including how patient cases are described in written
referrals to other clinics and in clinical conferences and
tutoring). Table 1 shows case IS as it was presented to par-
ticipants in the study. All previously shown information
about a case was repeated on the later screens to reduce
and control for memory effects. This part of the text was
placed at the top of the screen and was a different colour.
Procedure
The study was carried out between August and December
2000. The details of the procedure have been described
previously [8]. In the course of six screens, more clinical
information was gradually added to the case. The partici-
pants were instructed to voice aloud all their thoughts
about the case, and were told that each case would end
with the question as to whether or not they would pre-
scribe a drug for this patient.
Table 1: Example of a Case (IS)
Screen Information
1 The patient is a 67-year-old woman whose recent cholesterol value was 7.3 mmol/L. She has had the diagnosis 
hypercholesterolaemia for two years. She has been given advice concerning diet but she has not been prescribed a cholesterol-
lowering drug. Her cholesterol value has decreased from an initial value of 7.8 mmol/L
2 The patient has been on medication for hypertension for 10 years (Seloken ZOC* 50 mg and Plendil** 5 mg). She is now on a 
visit to check her blood pressure and hypercholesterolaemia.
3 The patient has no other known diseases apart from osteoarthritis of her knees. Her mother suffered from hypertension and 
reached the age of 84 years.
4 The patient is a non-smoker. She very seldom drinks alcohol. She does not exercise on a regular basis but she is fond of taking 
walks.
5 Physical examination: Good general condition. A few kilograms overweight. Blood pressure 145/75. Heart and lung auscultation 
normal.
6 Laboratory values: Total cholesterol 7.3 mmol/L. LDL 5.4 mmol/L. HDL 1.2 mmol/L. Triglycerides 1.6 mmol/L. TSH, creatinine 
and liver-function tests were normal.
7 Would you prescribe a cholesterol-lowering drug for this patient?
Yes  No BMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/3
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After the six cases the participants were asked to describe
in their own words how they usually reason when con-
fronted with patients for whom drug treatment for high
cholesterol values could be considered (Free Reports).
The study was approved by the local ethics committee.
Response measures and coding of data
Decisions
Each case ended with a screen (screen seven) with the fol-
lowing question: "Would you prescribe a cholesterol-low-
ering drug for this patient?" The participant responded by
clicking on one of two response alternatives, "Yes" or
"No".
Think-Aloud Protocols
The sessions were tape-recorded. A secretary then tran-
scribed the recorded sessions into a written, word-by-
word format. The protocols were segmented into state-
ments. For the purpose of the present paper, the Think-
Aloud Protocols were searched for two aspects, arguments
concerning the decision to prescribe or not to prescribe,
and (as described under Free-Report Protocols below) cer-
tain cause-effect relations. The criteria for an argument
were that it should be voiced in connection with a state-
ment indicating the decision (or a consideration of the
decision) and that it should be interpreted by the coder as
providing increased understanding of the decision. The
following are examples of such statements. "I say no
because I would like her diabetes to be under better con-
trol and her weight reduced or for her to get more physical
exercise." (Diabetic case GM, Participant No. 11); "I think
his cholesterol value is so close to normal and the diagno-
sis of angina pectoris seems to be unclear, so I would hes-
itate to prescribe" (CHD case AR, Participant No. 4).
In the original coding, the statements were also catego-
rised with respect to the cognitive content, their direction-
ality in relation to the decision (speaking for or against
drug treatment), and finally which information about the
case the statement referred to. These aspects of the coding
are described in previous papers [8,9] and are not used in
the present article.
Free-Report Protocols
The protocols from the Free Reports were segmented into
statements. The set of statements was thereafter analysed
for cause-effect relations according to the method
described by Axelrod [10]. (As the Free Reports were not
related to the different cases, coding for decision argu-
ments was not considered relevant). Both causes and
effects are variables in the sense that they can have differ-
ent values. In the present context, cause variables are
mainly patient-describing variables, e.g. age, presence or
absence of different medical conditions, and laboratory
values. A cause can be a single variable or a combination
of other cause variables, e.g. elevated cholesterol in com-
bination with hypertension.
The coding resulted in 34 different single cause variables
and 39 different combinations of two or three of the same
cause variables, i.e. altogether 73 different causes affecting
an effect variable. We originally coded 23 different effect
variables. The result was a number of cause-effect relations
that were not directly relevant to the task in question (e.g.
increased alcohol intake causing an increase in Triglycer-
ides levels). We present only cause-effect relations that
include three effect variables that were judged to be perti-
nent to the task the doctors were instructed to carry out.
Usability
This effect variable indicates that a certain type of infor-
mation (cause) is useful for the decision situation without
referring to the probability for a prescription. Examples of
expressions by the participants (with the cause expression
within parentheses) were: " It's of little use...(to refer to a
specialist)"; " I often look at ...(risk tables)".
Probability
A general influence on the probability for drug prescrip-
tion is exemplified by the following statements (causes
within parenthesis): Participant No. 13- "(The patient's
own opinion)...affects my willingness to prescribe"; Par-
ticipant No. 8- "(If the patient is very old...and consider-
ing the cost of drugs) you should really think twice before
prescribing a drug ".
Implication
If, on the other hand, the effect seemed to be a definite or
almost definite prescription given the cause variable(s) at
hand, the effect variable was termed "Implication". Exam-
ples of statements coded in this way were (causes within
parentheses): Participant No. 1- "I treat patients with
(ischaemic heart disease)"; Participant No. 4- "(If the
patient is young, has a level below 8, and no other dis-
eases) I wouldn't treat it".
We did not distinguish between positive and negative
directions (or other possible kinds of relations as specified
by Axelrod [10]) in the cause-effect relations. The relation
between cause and effect can be positive in the sense that
an increased value, or presence, of the cause variable leads
to an increased value in the effect variable. For example,
increased age of the patient leads to a higher probability
of drug prescription. Correspondingly, a negative relation
implies that an increased value of the cause variable leads
to a decreased value of the effect variable. In some
instances, the direction could be understood tacitly and in
other instances it could not be determined (e.g. when a
participant stated that smoking affected the probabilityBMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/3
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for drug prescription but not whether the impact was pos-
itive or negative). Due to a fairly large number of such
implicit or undeterminable directions, we did not distin-
guish between different kinds of relations between causes
and effects in the data presentation. In a few cases when
an effect was also a cause of a different effect variable (i.e.
a chain of cause-effect relations), we analysed this as two
separate cause-effect relations.
Results
Our main purpose was to investigate how the doctors use
their guidelines knowledge and what arguments they give
for their decisions on drug treatment. First, however, we
will give an overview of the Free-Report Protocols. There-
after, we will combine the three different kinds of data
(decisions, cause-effects relations and arguments) to try to
elucidate the decisions on the different cases.
Contents of the Free-Report Protocols
Reliability
Two of the authors (LB and YS) coded 50 randomly
selected statements from the Free-Report Protocols inde-
pendently of each other. Before that, and in order to get a
common understanding of how the variables were
defined, an initial coding of another 10 randomly selected
statements was performed and, when necessary, differ-
ences in opinions were discussed and resolved. The cause
and effect variables in the presentation of the final results
(Table 2) were used. For 39 (78%) of the statements there
was complete agreement as to the cause variable or varia-
bles. The same rate of agreement (78%) was found for
effect variables. There were 31 statements (62%) in which
there was agreement regarding both cause(s) and effect.
The total number of coded relations with the three effect
variables Usability, Probability and Implication was 200,
or on average 10.0 per doctor. The most frequent effect
variable was Probability (mean 6.1), followed by Implica-
tion (mean 2.4) and Usability (mean 1.5). The vast major-
ity (82%) of the coded relations were restricted to one
cause variable, 14.5% to two and 3.5% to three cause var-
iables in combination. It can be noted that four of the
seven relations with three causes stemmed from one par-
ticipant. Nine of the 20 participants gave no relations with
more than one cause variable. There was considerable var-
iation in the length of the Free Report Protocols of the dif-
ferent participants. The number of words varied between
158 and 773, and the number of cause-effect relations var-
ied between two and 22.
Table 2 shows the number of expressed relations contain-
ing different cause variables related to the three different
Table 2: The frequencies of different cause-effect combinations in the Free-Report Protocols.
Cause variable Effect variable No. of Drs
Usability Probability Impli cation Total
Cholesterol/ Lipid Level 4 11 19 34 12
CHD 1 8 12 21 7
Diabetes 0 11 9 20 15
Family History 0 10 7 17 14
Age 1 12 2 14 7
Smoking 0 11 0 11 11
Cardio-Vascular Disease 0 3 8 11 8
Risk Level/Risk Chart 5 4 1 10 9
L i f e  S t y l e  C h a n g e / F a c t o r s 02795
L D L 17196
H y p e r t e n s i o n 06286
P a t i e n t ' s  A t t i t u d e 07186
P A D 03474
H D L 06174
S t r o k e / T I A 13264
O v e r w e i g h t 06066
S i d e  E f f e c t s  o f  D r u g s 03033
E x e r c i s e 03033
P a t i e n t ' s  S e x 03032
A l c o h o l  C o n s u m p t i o n 02022
C o s t / C o s t  B e n e f i t 11022
L o c a l  O r g a n i s a t i o n 20022
D r - P a t i e n t  R e l a t i o n 20022BMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/3
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effect variables. The frequencies include instances when
the cause variable was expressed either alone or in combi-
nation with one or two other cause variables. The last col-
umn shows the number of doctors out of 20 who had the
different cause variables included in their cause-effect rela-
tions. For the sake of clarity, some cause variables have
been aggregated, e.g. Patient's Attitude (includes Motiva-
tion and Opinion among other original cause variables)
and Cardio-Vascular Disease (includes Heart Disease and
Cerebro-Vascular Disease). A specific combination of
cause(s) and effect was not coded more than once for
every participant, but it was possible for a participant to
have both Probability and Implication, for example,
related to the same cause. The cause variables are ordered
from top to bottom with regard to the total frequencies of
relations coded. Cause variables with a frequency of at
least two are included in Table 2. Cholesterol level was the
most frequent cause variable, followed by CHD, Diabetes,
Family History and Age in decreasing frequency. If we
restrict the analysis to single cause variables, Diabetes was
the most common variable, followed by Smoking, Age
and the combined variable Risk Level/Risk Chart. Diabe-
tes was also the cause variable with the highest probability
of being represented in a doctor's protocol, followed by
Family History. The most frequent single cause-effect rela-
tion was Smoking affecting Probability, which was
present for 12 of the 20 participants. As single cause vari-
ables, life-style factors (like Smoking and Overweight)
and Family History caused changes in the probability of a
drug prescription, but never to the extent that it was coded
as implying drug prescription. The variable Life-Style
Change/Life-Style Factors was related to Implication when
combined with other causes, but restricted to Probability
when it was a single cause variable. There were a few rela-
tions with cause variables outside the traditional risk fac-
tors. The most common was the Patient's Attitude with
Probability as effect for seven participants and Implica-
tion for one participant. Other such cause variables were
Side Effects of Drugs, Cost-Benefit considerations and
local resources and routines ("Local Organisation"). The
variables that most often affected Usability were Risk
Level/Risk Chart and Cholesterol/Lipid Level.
Evidence of knowledge related to guidelines
The cause variables of interest for this part of the analysis
were Diabetes, CHD, Stroke/TIA, and PAD. The latter
three variables were also analysed as subgroups of the
more general terms Cardio-Vascular Disease (relevant for
all three cause variables), Heart Disease (relevant for
CHD) and Cerebro-Vascular Disease (relevant for Stroke/
TIA). Table 3 shows the number of doctors who expressed
relations in the Think-Aloud Protocols and the Free-
Report Protocols containing these different cause varia-
bles (alone or in combination with other cause variables)
and the effect variables Probability and Implication. There
were only two instances when Usability was related to
these cause variables, one for Stroke and one for Heart
Disease, and these figures are not included in Table 3. If a
protocol from a participant contained both Probability
and Implication for a certain cause variable, only Implica-
tions was counted.
Fourteen of the 20 doctors indicated that CHD alone, or
in combination with other patient variables, should lead
to drug prescription (Implication), and this was the case
for a few more of the doctors if the cause variable was
generalised to Cardio-Vascular Disease or Heart Disease.
For Diabetes, the figure was 11 out of 20. If we include
Probability, practically all the doctors revealed having this
knowledge regarding Diabetes and CHD in one or two of
the protocols. It also seems that most of the knowledge
concerning CHD and Diabetes was manifested in the
Think-Aloud Protocols and that little was added in this
respect by also taking the Free-Report Protocols into
account. Few doctors expressed the association regarding
Stroke/TIA and PAD even if the more general terms car-
dio-vascular and cerebro-vascular diseases were included.
This is to be expected, as CHD and diabetes were repre-
Table 3: The number of doctors with protocols containing cause variables relevant for secondary prevention and diabetes.
Cause variable Think aloud (TA) Free report TA or Free report
Probability Implication Probability Implication Probability Impli cation
C H D 5 1 2 165 1 4
CHD or Cardiovascular-, or Heart Disease 5 14 3 11 3 17
Diabetes 10 9698 1 1
S t r o k e / T I A 001313
S t r o k e / T I A  o r  C a r d i o / C e r e b r o - v a s c u l a r  D i s e a s e 224537
P e r i p h e r a l  A r t e r y  D i s e a s e 000404
Peripheral Artery Disease or Cardiovascular 
Disease
211708BMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/3
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sented in the case vignettes, whereas no patient had a cer-
ebro-vascular disease or PAD, nor were these diseases
explicitly denied in the case descriptions.
Decisions and arguments
Table 4 shows the percentage of doctors who decided to
prescribe for the different patient cases along with the cen-
tral characteristics of the cases. The order of the cases in
Table 4 follows the presentation below, while the order of
occurrence for the participants was IS-GM-TW-SH-AR-PU.
CHD case
For the CHD case (AR), the presence of angina pectoris
should be a strong indication for drug therapy. Of the 20
doctors, 17 decided to recommend a drug. The number of
doctors who expressed the effect variable Implication
regarding CHD or Cardio-Vascular Disease was 17 as well.
There was no overlap between the group of three who
decided to refrain from treatment and the three who did
not express this knowledge. From the Think-Aloud Proto-
cols we found that one of the three doctors who refrained
from treatment questioned the diagnosis of angina pec-
toris and two suggested that weight reduction should be
further encouraged before starting drug treatment.
Diabetic case
For the diabetic case (GM), 10 of the 20 doctors suggested
drug prescription. In the "Yes" group six out of 10 verbal-
ised Implication. In the "No" group the corresponding
number was five. If we also incorporate Probability, the
numbers were 10/10 in the Yes- group and 9/10 in the
"No" group. In other words, almost every doctor stated
that diabetes in combination with hypercholesterolaemia
increases the reason to prescribe a cholesterol-lowering
drug, and there was no clear difference between those who
finally decided to recommend a drug and those with the
opposite decision in this respect.
Using the Think-Aloud Protocols we can examine the rea-
sons given by the 10 doctors who chose to refrain from
treatment. Three doctors expressed an inclination to pre-
scribe a drug but said at the same time that they preferred
to wait and see. Two doctors said that they wanted to
await further change in life-style. Another three doctors
seemed to have identified arguments against treatment
(lack of other diseases and risk factors, a mild form of dia-
betes, marginally elevated cholesterol). Two of the 10 doc-
tors who decided to refrain from treatment gave no clear
motivation in their verbal protocols (e.g. Dr 2: " I don't
think we have anything to gain").
Primary prevention cases
The high-risk case (TW) is the first of the primary preven-
tion cases to be examined here. The presence of smoking
and hypertension in this 67-year-old male with a choles-
terol value of 6.0 mmol/L gives a 10-year risk in the range
of 20–40% when the risk chart is applied, which would
justify pharmacological treatment. However, this was the
choice of only 35 % of the participants. The following are
examples of arguments expressed by 13 of the doctors
who decided not to prescribe. Six doctors said that the
patient should stop smoking first, two that physical exer-
cise should be tried first. One doctor seemed to use the
moderate cholesterol elevation as an argument for not rec-
ommending a drug. For the remaining four non-prescrib-
ers no clear arguments for their decision could be found
in the protocols. Among the seven who chose to prescribe,
four seem to have used the patient's inability to change his
life-style as their motivation and the other three men-
tioned multiple risk factors. In other words, life-style fac-
tors seemed to have been important in making the
Table 4: Description of the six cases and the percentage of doctors who decided to prescribe for each case.
Case Cholesterol  
value (mmol/L)
Additional risk factors Recommended 
management
Estimated risk in 
percentage by chart
Percentage of doctors 
who decided to prescribe
AR
(male, 56)
5.9 CHD, Overweight Yes (CHD) * 85
GM
(female, 53)
5.9 Diabetes, slight Family History Yes (diabetes) 10–20 (moderate) 50
TW
(male, 67)
6.0 Hypertension, Smoking Yes (risk above 20%) 20–40 % 35
IS
(female, 67)
7.3 Hypertension, slight Family History No (risk below 20%) 10–20 (moderate) 60
PU
(female, 41)
7.2 Strong Family History No (risk below 20%) 
**
10–20** 70
SH
(female, 51)
6.5 No additional risk factors No (risk below 20%) 5–10 (mild) 0
* Risk estimation is not considered relevant in the presence of CHD ** Family history or Familial hypercholesterolaemia are not directly included in 
the chartsBMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/3
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decision, but as an argument both for prescribing and for
not prescribing.
Case IS represents a patient with moderate risk (10–20%),
which would ordinarily not motivate drug treatment.
However, 12 of the 20 participants (60%) chose to pre-
scribe. Ten of the 12 prescribers for Case IS gave hyperten-
sion as an argument and four of these also mentioned the
degree of cholesterol- and/or LDL elevation as well. One
of the four also included the information about family
history. One of the doctors who chose to prescribe gave no
argument for his/her decision and one merely stated that
life-style intervention had not succeeded. For the eight
non-prescribers, we could not find any argument for their
decision in four of the verbal protocols, whereas two doc-
tors stressed the small number risk factors, one that the
patient was female and had a high HDL, and one that the
patient was a non-smoker and had a mother who had
reached an advanced age.
Case PU describes a young female with no risk factors
other than a fairly high cholesterol/LDL and a severe fam-
ily history of coronary heart disease. The case may qualify
as "probable familial hypercholesterolaemia" [11]. A sim-
ple application of the risk chart would give a mild risk (5–
10%) or, more correctly, a moderate risk (10–20%) if the
time span were projected to the age of 60 years. However,
the severe family history should be taken into account,
which would make drug treatment reasonable. The major-
ity (14 of 20 or 70%) chose to prescribe. All the prescrib-
ers gave family history as an argument for drug treatment
and four seemed to have considered the diagnosis familial
hyperlipidaemia. Of the six non-prescribers, three gave no
apparent argument for their decisions; two appeared to
have used the patient's young age and long expected treat-
ment time as an argument against prescription. The sixth
non-prescriber apparently considered a number of risk-
lowering factors (female sex, normal weight, non-smok-
ing and physically active) as arguments against treatment.
Case SH represents a low-risk case (5–10%) and all doc-
tors chose not to prescribe. As arguments for their deci-
sions, 11 doctors used terms like "no risk factor other than
elevated cholesterol", four referred to the absence of other
important diseases – diabetes, cardiovascular disease and
hypertension, one doctor stated that the case did not
concern secondary prevention, whereas another four doc-
tors gave no clear reasons for their decision.
Discussion
Our purpose was to study the relation between the doc-
tors' knowledge of guidelines and their decisions on
patient cases. The concept of guidelines and evidence-
based medicine implies, simply speaking, that patients
should receive uniform treatment regardless of which doc-
tor they happen to meet. The degree of consensus among
the 20 doctors regarding the decisions varied considerably
for the six cases – from a complete consensus on case SH
to maximum possible variability in "Yes" and "No "deci-
sions for case GM. At first glance, this might seem prob-
lematic as regards the quality of care for this patient
group. However, when we combine the decisions with
evidence of guideline knowledge and arguments for the
decisions, the management of the different cases seems
rather understandable. The diabetes case with as many
"Yes" decisions as "No" decisions had only a marginally
increased cholesterol level. For both of the cases that
could be solved by applying a rule from the guidelines
(i.e. the CHD case, AR, and the diabetes case, GM), there
were several instances where a doctor seemed to know the
content of the guidelines but nevertheless decided to
depart from it. There seemed to be two types of arguments
for the decision not to follow the guidelines strictly. One
was the absence of risk factors other than hypercholester-
olaemia. The other was giving priority to a life-style
change rather than to drug treatment. For example, the
patient should try to quit smoking or lose weight rather
than start lipid-lowering medication. It is noteworthy that
life-style factors could be used as an argument for deci-
sions in two different ways. A modification of life-style
could be seen as a means of reducing the total risk and
thus as an alternative to drug treatment as previously dis-
cussed, or life-style could be seen as a risk factor per se.
This is illustrated by Case TW: some participants viewed
smoking cessation as an alternative action to drug treat-
ment, while others used smoking as risk-increasing factor
and therefore as an argument for drug treatment.
The decisions on the high-risk patient (TW) with several
risk factors suggest a tendency to underestimate total risk
for patients with many simultaneous risk factors (only
seven of the 20 participants suggested drug prescription
whereas the risk chart puts him in a high-risk category).
This is in line with a previous study [4] where the task was
to make numerical risk estimates of patient cases with ele-
vated cholesterol values and different patterns of other
risk factors: there was a tendency to underestimate risk,
especially so for high-risk patients. However, other studies
have shown a tendency for doctors to underestimate the
absolute risk for coronary events when they make intui-
tive judgements [12,13].
For case IS with a moderate risk (implying no drug treat-
ment) there was no evidence of under-treatment in rela-
tion to risk estimates and guidelines, as the majority
(60%) decided to prescribe.
The analysis of the Think-Aloud Protocols and the Free-
Report Protocols implied a high degree of knowledge con-
cerning two central aspects of the guidelines, the specialBMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/3
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treatment indications for patients with CHD and patients
with diabetes. On the other hand, only a minority of the
doctors stated that Stroke/TIA or peripheral artery disease
were important as indications for drug treatment in the
same sense as CHD and diabetes. There can be two rea-
sons for this. Our choice of patient cases could be rele-
vant. None of the cases had these diseases nor were the
conditions denied in the descriptions, and consequently
the doctors were not reminded of their existence. Sec-
ondly, the message that these arterio-sclerotic manifesta-
tions should be as important criteria for drug prescription
as CHD and diabetes was quite new when the study was
conducted (the guidelines were published in 1999 and
the study was carried out in 2000), and it is possible that
the doctors were not completely cognizant of this part of
the guidelines.
Quite a few factors other than the traditional risk factors
were found as cause variables in the Free-Report Proto-
cols. The two most frequent variables both affected Prob-
ability, and they were the Patient's Attitude, including
Willingness to Take Drugs, and Side-Effects of Drugs. It
can be noted that in spite of the recurrent debate concern-
ing high drug costs for cholesterol treatment, there were
only two doctors who mentioned drug cost or cost-benefit
considerations as factors influencing the decision or deci-
sion situation.
The Free-Report Protocols coded as cause-effect relations
were supposed to reflect factors of importance regarding
the decision to prescribe or not to prescribe a lipid-lower-
ing drug. A comparison with the Think-Aloud Protocols
from when the cases were processed, which is described in
a separate paper [9], can lend some support to the validity
in this respect. The different factors describing the patients
were compared with regard to how often they were evalu-
ated in a positive or negative way in relation to drug pre-
scription. The six most important factors, in descending
frequencies, were Cholesterol, Smoking, Hypertension,
Family History, CHD and Diabetes. Approximately the
same set of important variables was found in the Free-
Report Protocols (see Table 2), in descending frequencies:
Cholesterol, CHD, Diabetes, Family History, Age and
Smoking.
The guidelines may be too simple in the sense that the
same cut-off values for total cholesterol and LDL are used
for all patients with established arterio-sclerotic disease or
diabetes, regardless of the levels of their other risk factors.
Our diabetes case demonstrated that an application of the
risk chart suggests a different decision than simply apply-
ing the rule that diabetics should be regarded as on a par
with secondary prevention cases. It can be noted, how-
ever, that the guidelines that were just recently published
in Sweden [14] indicate that the threshold for patients at
very high risk should be lower than 5.0 mmol/L. Further-
more, the validity of the Framingham equation can be
questioned on at least two grounds. One concerns the risk
factors included. A severe family history of CHD should
increase the risk substantially, but this risk factor does not
enter into the Framingham formula. The other concerns
the generalisability of the Framingham equation to new
populations. There is agreement that the Framingham
equation overestimates risk for populations with a low
incidence of CHD [15], but recent results also indicate
over-estimations for northern European samples [16].
Decisions on drug treatment or not in the primary preven-
tion situation could be based on a formal or intuitive risk
estimate. Intuitive risk estimates seem to be systematically
biased [4,12,13]. There is also evidence that tools for risk
estimates are seldom used [17], or little known [18] by
different groups of European GPs. The data from the
present study indicate that most doctors make the distinc-
tion between primary and secondary prevention in their
decisions, but that recent modifications of the guidelines,
e.g. the importance of previous stroke, is less well imple-
mented. In the implementation of guidelines on preven-
tive cardiology and lipid treatment there is a need not
only to improve the availability and usability of guide-
lines, but also to make clear the distinction between pri-
mary and secondary prevention in a broader sense and to
update the guidelines with risk assessment tools based on
relevant risk data.
Limitations of the study
Conclusions concerning the participants' knowledge of
certain aspects of the guidelines should be viewed in light
of the method used. The validity of verbal protocols,
including the coding procedure, can be questioned on
several grounds. We did not interview the doctors directly
about the guidelines but rather asked them to describe
freely how they usually reason in connection with the
decision situation at hand. It is possible that factors such
as communication style, concentration, memory and
tiredness might lead to an underestimation of knowledge
on the part of the doctors. On the other hand, Free-Report
Protocols and Think- Aloud Protocols have the advantage
as compared to other information acquisition methods,
involving more asking specific questions to the doctors,
that they are minimally affected by the investigator's
expectations. The Free-Report Protocols may have been
affected by the decisions made in the previous cases as the
participants may have strived to be consistent. Also, as dis-
cussed earlier, conditions that were not mentioned in the
case descriptions (like Stroke/TAI) probably had a smaller
chance to be mentioned in the Free-Report Protocols.
Another aspect of the validity problem concerns the con-
gruence between medical knowledge and responses toBMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/3
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simulated patient cases. Results from a think-aloud study
by Kaufman and coworkers [19] regarding cases of hyper-
cholesterolaemia and coronary heart disease suggest that
medical knowledge is not always used adequately in deci-
sions on patient cases.
The coding procedure may also be questioned, as the dis-
tinction between the effect variables Probability and
Implication was not always self-evident, even if the inter-
judge reliability could be considered as reasonable (78%).
Another problem was that participants used different lev-
els of abstraction when talking about diseases. For exam-
ple, we could not know how many of the diseases in
question, Stroke/TIA, CHD and PAD, were tacitly under-
stood and encompassed by the expression "Cardio-Vascu-
lar Diseases". Finally, the coding of Think-Aloud
Protocols for decision arguments was made by only one of
the authors and the reliability has not been determined.
The purpose of the study was restricted to examining deci-
sions without access to guidelines. A comparison of infor-
mation processing and decisions with and without
guidelines would be interesting. Patel and co-workers [20]
used think-aloud technique to contrast performance with
and without access to guidelines. They found that guide-
lines seemed to be used differently and serve different pur-
poses by physicians at different level of expertise, a result
that should have implications for the design of guidelines.
The number of cases in this study was small, and conclu-
sions concerning different kinds of patient cases must be
drawn with caution. Both the diabetic case and the CHD
case had few other risk factors and the doctors' departure
from a strict application of the guidelines should be
viewed in this light. A better assessment of their adherence
to guidelines with secondary prevention cases and diabe-
tes would have required a larger set of cases with different
degrees of cholesterol levels and other risk factors.
The analyses were done at a group level and no evaluation
was carried out concerning how consistent individual
doctors were across cases.
The GPs in the study were recruited from a limited geo-
graphical area, the southern part of Stockholm, and they
may not be representative of Swedish GPs as regards
knowledge in the medical field or the availability of local
decision supports. Thus, it is possible that another sample
of doctors would be quite different in their prescription
decisions as well as the importance attributed to different
patient characteristics.
Conclusions
One conclusion from the present study is that coding of
verbal protocols for knowledge and for decision argu-
ments is a valuable tool for increasing our understanding
of how guidelines are used in decisions on realistic patient
cases. Another conclusion is that it is problematic to use
existing guidelines on lipid management and associated
risk charts as a simple means to evaluate the quality of
care for patients with hypercholesterolaemia.
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